NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 34-12100-03

Docket or Reference number: 030-08523

Amendment No. 22

St. Rita's Medical Center
730 W. Market Street
Lima, OH 45801

In accordance with application dated October 25, 1984, License Number 34-12100-03 is amended as follows:

Items 6., 7., 8., and 9. are amended to add:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Phosphorus-32	G. Colloidal chromic phosphate received, possessed or used in accordance with the provisions of Section 35.14(b)(1), 10 CFR 35	G. 50 millicuries
H. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	H. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	H. 1,000 millicuries total for all sources authorized in Subitem 6.H

9. Authorized Use

G. For intracavitary treatment of malignant effusions.

H. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

T. D. Allison, M.D.	Groups I, II and III In vitro procedures Xenon-133
Mostafa Norri, M.D.	Groups I, II and III In vitro procedures Xenon-133
Thomas K. Wu, M.D.	Groups I, II and III In vitro procedures Xenon-133

COPY 2 of 2
mt 30
AS 5/24/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 34-12100-03

Docket or Reference number 030-08523

Amendment No. 22

Homer H. Cheng, M.D.	Group I In vitro procedures
Kalman O. Pajor, M.D.	Group I In vitro procedures
LeRoy L. Schroeder, M.D.	Iodine-131 for diagnosis of thyroid function and treatment
Fred F. S. Chang, M.D.	Groups I, II and III In vitro procedures Xenon-133
George M. Parker, M.D.	Groups I, II and III Iodine-131 for therapy In vitro studies
Thomas E. Dicke, M.D.	Licensed material of the types, quantities and forms specified in Sections 35.31(a) of 10 CFR 35 and 31.11(a) of 10 CFR 31 in accordance with the provisions of paragraphs (a) and (c) of Section 35.31, 10 CFR 35 and paragraphs (a), (c), and (d) of Section 31.11, 10 CFR 31
Carl Schweizer, M.D.	Licensed material of the types, quantities and forms specified in Sections 35.31(a) of 10 CFR 35 and 31.11(a) of 10 CFR 31 in accordance with the provisions of paragraphs (a) and (c) of Section 35.31, 10 CFR 35 and paragraphs (a), (c), and (d) of Section 31.11, 10 CFR 31
Michael Holmes, M.D.	Licensed material of the types, quantities and forms specified in Sections 35.31(a) of 10 CFR 35 and 31.11(a) of 10 CFR 31 in accordance with the provisions of paragraphs (a) and (c) of Section 35.31, 10 CFR 35 and paragraphs (a), (c), and (d) of Section 31.11, 10 CFR 31
Robert Field, M.D.	Groups I, II, III and VI Xenon-133 In vitro studies Phosphorus-32 for intracavitary treatment of malignant effusions

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 34-12100-03

Docket or Reference number 030-08523

Amendment No. 22

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated April 27, 1982, February 2, 1984, and October 25, 1984; letter dated May 31, 1982; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Conditions 20. and 21. are added:

20. Sealed sources containing licensed material shall not be opened.

21. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for five (5) years from the time the implants are removed.

For the U.S. Nuclear Regulatory Commission

Date May 24, 1985

Original Signed
By Evelyn R. Matson
Materials Licensing Section, Region III

COPY